Universal Vision Biotechnology Co

Universal Vision Biotechnology Co EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Universal Vision Biotechnology Co (3218.TWO) as of Nov 1, 2026 is 6.89. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 7.50 — a change of -8.10% (lower).

EV/OCF

6.89

YoY

-8.10%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Universal Vision Biotechnology Co is 2025 6.89 . EV/OCF (Enterprise Value to Operating Cash Flow) of Universal Vision Biotechnology Co was 2024 7.50 . It decreases by -8.10% lower compared to the previous year.

The Universal Vision Biotechnology Co EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
42.60 TWD
Jan 1, 2019
27.08 TWD
Jan 1, 2020
13.32 TWD
Jan 1, 2021
12.29 TWD
Jan 1, 2022
8.66 TWD
Jan 1, 2023
6.83 TWD
Jan 1, 2024
7.50 TWD
Jan 1, 2025
6.89 TWD
The Universal Vision Biotechnology Co EV/OCF history
YEAREV/OCFYoY
6.89-8.10%
7.50+9.69%
6.83-21.10%
8.66-29.54%
12.29-7.71%
13.32-50.81%
27.08-36.43%
42.60-13.00%
48.97+6.60%
45.94-28.48%
64.23+20.20%
53.44—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Universal Vision Biotechnology Co Stock analysis

What does Universal Vision Biotechnology Co do? Universal Vision Biotechnology Co., Ltd. generates revenue through the sale of optical instruments, glasses, contact lenses, and glass ornaments. The company also provides laser vision correction equipment and services, trades medical drugs, and offers leasing of medical facilities, clinic operation planning, and medical cosmetology services. Its primary market is Taiwan, where it serves customers seeking vision correction solutions and medical aesthetic treatments. The firm's product portfolio includes optical instruments, glasses, contact lenses, and glass ornaments, alongside medical drug trading. Services such as laser vision correction, medical facility leasing, clinic operation planning, and medical cosmetology are key revenue drivers. Taiwan-based customers, including individuals requiring vision care and clinics needing operational support, form the core market segment. Revenue streams are derived from the direct sale of optical products, medical drug trading, and service-based offerings like laser vision correction and medical cosmetology. The company operates exclusively within Taiwan, focusing on both consumer and clinic-level clients for its comprehensive vision and medical aesthetics solutions. Universal Vision Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Universal Vision Biotechnology Co stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Universal Vision Biotechnology Co is 6.89 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Universal Vision Biotechnology Co changed from 7.50 to 6.89, representing a -8.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Universal Vision Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Universal Vision Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Universal Vision Biotechnology Co

All Key Metrics — Universal Vision Biotechnology Co